Dupixent® (dupilumab) approved in the european union as the first and only medicine for young children with eosinophilic esophagitis

Approval based on phase 3 data showing significantly more children aged 1 to 11 years on dupixent achieved histological disease remission at 16 weeks compared to placebo, which was sustained up to one year

REGN Ratings Summary

REGN Quant Ranking